Fluidigm FLDM 深 滬
等待開盤 09-17 09:30:00 美东时间
3.71
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 3.71
- 總市值 28.64万
- 52周最高 7.51
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.67
- 委 比 0.00%
- 總股本 7.72万
- 歷史最高 49.455
- 量 比 0
- 振 幅 0.00%
- 歷史最低 1.17
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026
Standard BioTools Inc. (NASDAQ: LAB) announced it will release its second quarter 2026 financial results on August 5, 2026, after U.S. market close. The company, committed to advancing life science tools through strategic initiatives, provides essential solutions for biomedical research. For more information, visit standardbio.com or contact investors via ir@standardbio.com.
07-22 11:00
Standard BioTools Completes Sale of SomaLogic to Illumina
Standard BioTools completed the sale of SomaLogic to Illumina for $350 million upfront, plus up to $75 million in earnouts and royalties. The transaction enhances the company's financial position, with $550 million in cash to fuel M&A growth. CEO Michael Egholm highlighted the strategic transformation and strengthened financial standing. The deal includes IP licenses and royalty streams, positioning the company for future expansion.
01-30 14:09
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
Standard BioTools Inc. reported preliminary, unaudited 2025 revenue of approximately $185 million for the combined company and $85 million from continuing operations, exceeding expectations. CEO Michael Egholm highlighted steady execution, cost optimization, and a focus on profitability amid macro challenges. The company expects to close the sale of SomaLogic to Illumina in the first half of 2026, resulting in $550 million in cash and a stronger ...
01-08 12:00
Standard BioTools Get a Buy Rating, Analyst Cites Unique Technology, Management and Board
KeyBanc Capital Markets initiated coverage on Standard BioTools Inc (NASDAQ: LAB) with an Overweight rating and a
2023-07-13 01:58
Standard Biotools Inc盘中异动 急速拉升5.03%报1.78美元
北京时间2022年07月08日00时01分，Standard Biotools Inc（LAB.us）股票出现异动，股价快速拉升5.03%。截至发稿，该股报1...
2022-07-08 01:08
Fluidigm宣布与Caligan Partners达成支持协议，涉及Casdin Capital和Viking Global的2.5亿美元战略资本注入
Caligan Partners to Vote "FOR" Casdin and Viking Transaction and All Other Flui...
2022-03-29 21:31
Fluidigm强调Casdin Capital和Viking Global的战略注资是唯一可行的融资解决方案
Company Urges ALL Stockholders to Vote "FOR" the Proposals at the Special Meeti...
2022-03-28 20:38
Fluidigm将股东特别会议延期至2022年4月1日
Provides Stockholders Additional Time to Consider $250 Million Strategic Capita...
2022-03-26 04:06
领先的独立代理咨询公司ISS和Glass Lewis建议Fluidigm股东投票支持与2.5亿美元战略资本注入有关的所有提案
Fluidigm Board of Directors Unanimously Recommends Stockholders Vote "FOR" ALL ...
2022-03-18 06:02
Fluidigm公司宣布与阿布扎比干细胞中心达成合作协议，以加快成像质谱技术在定向干细胞疗法开发中的应用
Collaboration Enables Further Expansion of Mass Cytometry in the Middle East SO...
2022-02-17 21:37
